Icon (NASDAQ:ICLR) Director Sells 3,452 Shares of Company Stock

by · The Markets Daily

Icon Plc (NASDAQ:ICLR – Get Free Report) Director Ciaran Murray sold 3,452 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $205.66, for a total value of $709,938.32. Following the completion of the transaction, the director directly owned 17,000 shares in the company, valued at $3,496,220. The trade was a 16.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Ciaran Murray also recently made the following trade(s):

  • On Tuesday, August 11th, Ciaran Murray sold 2,677 shares of Icon stock. The stock was sold at an average price of $164.29, for a total transaction of $439,804.33.

Icon Trading Down 0.7%

ICLR stock opened at $203.77 on Wednesday. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.37. Icon Plc has a twelve month low of $66.57 and a twelve month high of $219.04. The company has a market cap of $15.60 billion, a P/E ratio of 35.07, a PEG ratio of 11.53 and a beta of 1.19. The business has a fifty day moving average of $173.23 and a 200-day moving average of $146.72.

Icon (NASDAQ:ICLR – Get Free Report) last issued its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.62 by $0.04. The firm had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. Icon had a return on equity of 7.73% and a net margin of 5.45%. The company’s revenue was down .9% compared to the same quarter last year. During the same quarter last year, the business earned $3.31 earnings per share. As a group, equities research analysts expect that Icon Plc will post 9.57 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ICLR. Truist Financial increased their target price on shares of Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. BMO Capital Markets reissued an “outperform” rating and set a $235.00 price target on shares of Icon in a research report on Thursday, October 29th. Bank of America upgraded shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price objective for the company in a research note on Friday, October 9th. TD Cowen raised their price objective on Icon from $197.00 to $254.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $254.00 target price on shares of Icon in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Icon presently has a consensus rating of “Moderate Buy” and an average target price of $213.76.

Read Our Latest Report on Icon

Institutional Trading of Icon

Several institutional investors and hedge funds have recently bought and sold shares of ICLR. Principal Financial Group Inc. boosted its holdings in shares of Icon by 10.3% during the first quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after acquiring an additional 310,236 shares during the period. Trinity Street Asset Management LLP grew its position in shares of Icon by 27.1% in the second quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock valued at $266,725,000 after purchasing an additional 327,314 shares during the last quarter. Maple Rock Capital Partners Inc. increased its stake in shares of Icon by 257.8% during the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after purchasing an additional 864,300 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Icon by 50.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company’s stock worth $87,262,000 after purchasing an additional 265,858 shares during the last quarter. Finally, Sound Shore Management Inc. CT acquired a new stake in Icon during the 1st quarter worth approximately $69,379,000. Institutional investors own 95.61% of the company’s stock.

Trending Headlines about Icon

Here are the key news stories impacting Icon this week:

  • Positive Sentiment: A reported consensus price target rose 23.33% to $239.19, suggesting improved analyst expectations and potential upside relative to the stock’s recent trading level. Article: ICON consensus price target increased
  • Positive Sentiment: A recent article highlights ICON’s use of AI to accelerate clinical trials. If these tools improve trial speed or efficiency, they could support the company’s value proposition to drug developers, though the report provides no specific financial impact. Article: ICON is leveraging AI to accelerate clinical trials
  • Neutral Sentiment: The CEO, CFO and chief accounting officer each sold shares on November 2. The reported sales were to cover tax withholding tied to vested equity awards, which makes them a weaker signal of insider concern than ordinary discretionary selling. Article: ICON chief accounting officer stock sale
  • Negative Sentiment: Director Ciaran Murray sold 3,452 shares for about $710,000, reducing his reported holdings by 16.88%. The filing did not provide a tax-withholding explanation, so the sale may add to investor concern about insider selling. SEC insider transaction filing

About Icon

(Get Free Report)

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.

Featured Articles